KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Short-term Investments (2016 - 2017)

Historic Short-term Investments for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Q4 2017 value amounting to $25.0 million.

  • Teva Pharmaceutical Industries' Short-term Investments fell 7159.09% to $25.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $25.0 million, marking a year-over-year decrease of 7159.09%. This contributed to the annual value of $25.0 million for FY2017, which is 7159.09% down from last year.
  • As of Q4 2017, Teva Pharmaceutical Industries' Short-term Investments stood at $25.0 million, which was down 7159.09% from $88.0 million recorded in Q4 2016.
  • Teva Pharmaceutical Industries' Short-term Investments' 5-year high stood at $105.0 million during Q4 2015, with a 5-year trough of -$366.0 million in Q4 2013.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Short-term Investments value was $82.0 million (recorded in 2014), while the average stood at -$13.2 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Short-term Investments crashed by 925000.0% in 2013, and later surged by 12240.44% in 2014.
  • Teva Pharmaceutical Industries' Short-term Investments (Quarter) stood at -$366.0 million in 2013, then surged by 122.4% to $82.0 million in 2014, then rose by 28.05% to $105.0 million in 2015, then dropped by 16.19% to $88.0 million in 2016, then crashed by 71.59% to $25.0 million in 2017.
  • Its Short-term Investments stands at $25.0 million for Q4 2017, versus $88.0 million for Q4 2016 and $105.0 million for Q4 2015.